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SUMMARY. Introduction. Adrenal hyperandrogenism (HA) exerts a negative effect on the women’s reproductive system 
(RS), while ovarian HA is preconditioned by the anovulation state. There are contradictory opinions on the infl uence of 
different androgens on the functions of women’s reproductive system. The main criteria of the assessment and impor-
tance of these factors remain undefi ned. Aim. In total, 105 women were examined and treated in the study, including a 
control group of women aged 19 to 37 (mean age 27,39±0,75), and patients with menstrual (opso- and oligomenorrhea) 
and reproductive (infertility and miscarriage) dysfunctions. Methods. The hormonal panel tests were also performed in 
the course of the menstrual cycle, on days 5–7 and 21–23, assessing the level of secretion of peptide and steroid sex 
hormones. Results. Combined HA is one of the leading pathogenic causes of menstrual and reproductive dysfunctions. 
Anovulation state causes an increase in the level of the main androgens, and the luteal phase defi ciency is a consequence 
of the negative impact of HA. Individual pathogenesis-based therapy, allows recovering ovulation and securing preg-
nancy against a background of normalization of androgen metabolism and other indicators of the reproductive system 
functioning. Conclusion. The criteria for differential diagnostics of hyperandrogenic states and assessment of reproduc-
tive dysfunctions allows fi nding an individual treatment pattern.
Introduction
One of the urgent problems of today’s gynaecological 
endocrinology is early detection of women’s reproduc-
tive dysfunctions.
Hyperandrogenism (HA) remains among the leading 
causes of reproductive system pathology; it is found in 
10–20% of all women of reproductive age.
The incidence of HA within the structure of gynaeco-
logical disorders is as much as 1,3–4% (1,2). Scientifi c 
literature contains a variety of defi nitions of “hyperan-
drogenism”, but most often this term is used for desig-
nating a set of symptoms of disorders associated with 
specifi c and metabolic effects of androgens in the fe-
male body due to pathological biosynthesis, transport 
and metabolism of androgens (3,4). HA syndrome is 
one of the most widespread causes for female reproduc-
tive disorders – oligomenorrhea, anovulation and, as a 
result, infertility (5,6). Besides, HA is manifested by 
complex symptoms of skin/skin appendages lesions 
(hirsutism, acne, alopecia, seborrhoea), collectively re-
ferred to as “androgen-dependent dermopathy”. It is 
common knowledge that in the female body, androgens 
are produced by both ovaries and adrenal glands (7). 
Detection of the source of HA is quite problematic, and 
diagnosis of a specifi c clinical form of HA is also diffi -
cult due to the polymorphism of this pathology and 
prevalence of its combined forms. However, distin-
guishing a particular HA form is defi nitely essential for 
detecting the source of HA and prescribing an adequate 
(in terms of pathogenesis) therapy (8). As of today, the 
most common pathology leading to the development of 
the HA syndrome is considered to be polycystic ovary 
syndrome (PCOS). PCOS is regarded as a poly-glandu-
lar, poly-etiologic and poly-symptomatic pathology, 
whose pathogenesis can be caused by disorders in both 
central and peripheral parts of the reproductive system.
In many studies, it was established that about 10% of 
women with PCOS also demonstrate symptoms of con-
genital adrenal hyperplasia (CAH) (9). It must be ad-
mitted that the ever-rising interest in the study of this 
pathology is limited by a number of diffi culties, which 
include heterogeneity and polymorphism of HA; this 
leads to considerable differences in diagnostic ap-
proaches, interpretation of diagnostic results or clinical 
evidence, specifi cs of the course of disease and choice 
of treatment tactics. Until now, the question of the 
cross-effects of the HA syndrome in the female body 
and reproductive system disorders remains disputed. In-
ternational scientifi c literature still lacks statistically 
signifi cant data on the dynamics of steroid hormones 
(estrogens and androgens) metabolism taking into ac-
count various indicators of reproductive system activi-
ty. All these data are usually related to attempts of mak-
ing a diagnosis in indeterminate cases. At that, the clini-
cal picture of combined HA greatly varies from case to 
case and may not correspond to current standard diag-
nostic criteria of certain diseases.
All stated above support the urgency of the problem 
and persuade of a need to improve the methods of ex-
amining HA patients, to search for optimal diagnostic 
criteria helping to identify a specifi c HA form, which is 
surely important for conducting an effi cient pathogene-
sis-related therapy.
The goal of the study is make a comprehensive as-
sessment of the reproductive system state and improve-
ment of the principles of menstrual/reproductive func-
tion recovery in patients with a combined form of HA, 
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to determine correlation between the main indicators of 
steroid hormones taking for different disorders of the 
reproductive system – corpus luteum insuffi ciency and 
anovulation.
Materials and Methods
This paper presents the results of examination and 
treatment of 105 women, including the control group. 
The patients were from 19 to 37 years old, the mean age 
was 27,39±0,75 years. 70 of them had symptoms of 
androgen-dependent dermopathy, with laboratory re-
sults indicative of HA, i.e. higher levels of free testos-
terone (FT) and total testosterone (TT), higher levels of 
androstenedione (An) and dihydrotestosterone (DHT). 
Combined HA was detected by signs of both adrenic 
HA (increased DHEAS, 17-ОНР and reduced cortisol 
(C)) and ovarian HA (LH >10 mIU/ml, LH/FSH >2, 
ovarian volume > 9 cm3, opsomenorrhea and primary 
infertility).
When selecting patients for all study groups, we ex-
cluded from consideration:
 – thyroid diseases;
 – hyperprolactinemia;
 – Cushing’s disease;
 – serious extragenital pathologies;
 – hormone-active androgen-producing tumours of 
ovaries and adrenal glands;
 – pathologies of the haemostasis system (genetic and 
acquired forms of thrombophilia).
The assessment of the patients’ state was carried out 
in compliance with a set of the HA diagnostic criteria:
 – Stage 1. Assessment of clinical HA symptoms: the 
signs of androgen-dependent dermopathy of differ-
ent intensity (acne, hirsutism, alopecia, etc.);
 – Stage 2. Evaluation of HA laboratory criteria: in-
crease in the level of the main androgens – TT, FT, 
An, and DHT;
 – Stage 3. Differential diagnostics of the HA form 
(source): adrenal, ovarian or combined.
This research clearly determined only criteria for 
PCOS diagnostics, including clinical criteria (luteal 
phase defi ciency and infertility), laboratory criteria (the 
LH level >10 IU/l on days 5–7 of the menstrual cycle) 
and instrumental criteria (the ovarian volume increase 
>9–10 cm3, detected by ultrasonic scanning of the pel-
vic organs) (10).
The patient groups were formed only on the basis of 
laboratory-confi rmed combined HA and the criteria of 
reproductive system functional activity – accomplished 
ovulation. The forms of the patients’ reproductive disor-
der (luteal phase defi ciency and anovulation) were de-
fi ned after the results of ultrasound and tests of hor-
mones in peripheral blood. The level of estradiol (E2) in 
peripheral blood on days 21–23 of the cycle defi ned the 
hormonal criteria of the reproductive disorder type: 
E2<350 pmol/l – hypoestrogenic, E2>750 pmol/l – hy-
perestrogenic, at the concentration of E2 between 350–
750 pmol/l and 16<Р<30 nmol/l – normoestrogenic or 
hypoprogesterone types.
Assessments of the reproductive function of patients 
with combined HA (CHA) were carried out on days 5–7 
and 21–23 of the menstrual cycle, which made it possi-
ble to divide the patients into two groups depending on 
the form of their reproductive disorder:
Group I CHA+A: 33 women aged 19–37 (mean age 
26,67±1,01) with anovulatory disorder of the reproduc-
tive system (with the menstrual cycle less than 21 or 
more than 35 days, endometrial thickness less than 6 
mm or more than 12 mm, absence of yellow body in the 
ovaries, progesterone level <15,9 nmol/l on days 21–23 
of the menstrual cycle).
Group II CHA+LPD: 37 women aged 20–38 (mean 
age 28,24±1,12) with luteal phase defi ciency (the men-
strual cycle of 21–26 days, the duration of the yellow 
body phase less than 10 days, sonographically measured 
endometrial thickness less than 10 mm and the size of the 
yellow body less than 20 mm, progesterone level 16–30 
nmol/l on days 21–23 of the menstrual cycle).
The control group was comprised of 35 apparently 
healthy women of a reproductive age (28,32±1,52 years 
old) having a regular ovulatory menstrual cycle of 28–
30 days, with no symptoms of HA.
When analysing anamnestic data and the results of the 
physical examination, we considered the following pa-
rameters: age, the state of the menstrual and reproductive 
functions, family history, anthropometric data, pelvis ul-
trasound, hormonal and non-hormonal state. The pelvic 
ultrasound was performed for all the patients in a stan-
dard way, in dynamic range, using the SonoAce-8000 
Live equipment produced by Medison (Korea), with ab-
dominal and vaginal sensors of 3,5 MHz, 5 MHz and 7,5 
MHz respectively. The hormonal panel tests were also 
performed in the course of the menstrual cycle, on days 
5–7 and 21–23, assessing the level of secretion of peptide 
and steroid sex hormones. All the patients were examined 
for non-hormonal homeostasis to reveal disorders of lipid 
and carbohydrate metabolism.
For successful treatment of menstrual and reproduc-
tion disorders, as the fi rst stage of ovulation stimulation 
in the cases of combined HA, we implemented a thera-
py with combined oral contraceptives (COCs) contain-
ing progestogens dienogest and drospirenone. As a hor-
monal support for the luteal phase of the menstrual cy-
cle, we prescribed natural micronized progesterone in 
the total daily dose of 200–300 mg, and an analogue of 
the endogenous progesterone, dydrogesterone, 10–14 
days with the total daily dose of 10–20 mg. In order to 
reduce the manifestations of androgen-dependent der-
mopathy and treat the hormonal dysregulations, we ad-
ministered dexamethasone in an individual daily dose 
of 0,125–0,5 mg. The treatment results were evaluated 
in 3, 6 and 9 months. Statistical processing of the ob-
tained data was carried out in Microsoft Excel (Micro-
soft, USA), SPSS–9.0 and Epi-info 6.0, with the use of 
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parametric and non-parametric methods. The para-
meters defi ned in the study were: mean value (M), stan-
dard deviation (σ), mean value error (m), and percent-
age in the data series (%). After checking normal distri-
bution of data, we used parametric methods (Student’s 
t-test). For correlation analysis of the parameters, we 
used Pearson correlation method. The critical value of 
signifi cance for all criteria was assumed to be equal 
to 0,05. The differences were taken to be signifi cant at 
P < 0,05 and highly signifi cant at P < 0,01.
Results
Russian and foreign researchers strongly recommend 
assessing the reproductive system state only after elimi-
nating all the cases of serious physical, endocrine and 
infectious diseases, which often cause menstrual and 
reproductive dysfunctions, because adequate work of 
all levels of the reproductive system is possible only 
under the conditions of physical and mental/emotional 
comfort, i.e. in a healthy female organism. Determi-
nation of only one marker – TT – is not, in our view, a 
suffi cient criterion of HA diagnosis, so HA can be con-
fi rmed only after simultaneous testing for all other ele-
ments actively participating in the metabolism of andro-
gens (TT, FT, An, DHT); they should be measured dy-
namically in the course of the menstrual cycle, in com-
bination with clinical data and the assessment of the 
reproductive system functional status. HA states evalu-
ated on days 5–7 of the menstrual cycle can be more 
evident in patients with a prevalent ovarian component, 
because of a considerable increase in the levels of the 
main androgens. The obtained results are in line with 
the opinion of some researchers (11) who consider a hy-
pothesis of the role of adrenarche in the ovarian HA 
genesis Higher levels of androgens are the results of an-
ovulation; at that, progressive increase in the levels of 
sex steroids exacerbates the anovulatory state.
In 69,2% of patients with CHA+A, the ovarian vol-
ume is increased (14,23±1,16 cm3, P < 0,01), while the 
follicular structure on days 5–7 of the menstrual cycle 
includes follicles sized 8–10 mm in diameter (8,37±0,62 
mm on average), which produce both estrogens and an-
drogens to an equal degree, therewith supporting the 
normo-estrogenic anovulatory state (12,13). The clini-
cal manifestations of reproductive system disorder in 
the group of patients with CHA+A include serious dys-
functions: the menstrual (opsomenorrhea – 60,6%, 
amenorrhea – 9,1%) and the reproductive one (infertil-
ity – 72,9%).To treat patients with CHA+A, we initially 
followed the simplest possible pattern of ovulatory 
stimulation by modern neutral metabolic COCs or the 
COCs that are not the derivatives of 19-norsteroids, 
since the latter exacerbate the HA state in the patients 
with CHA. Administering COCs, which contain such 
progestagens as dienogest and drospirenone, allows re-
ducing the functional capacity of the ovaries and the LH 
level due to recovery of the central regulatory compo-
nent of the reproductive system, as well as avoiding 
negative effects on the general metabolism and the me-
tabolism of androgens. The duration of treatment is in-
dividual for each clinical case and primarily depends on 
normalization of androgen metabolism indicators and 
normalization of the reproductive organs state, as well 
as on the reduction in the LH level and the LH/FSH ra-
tio during the fi rst three months of therapy. The treat-
ment should last for at least 4–6 months since this type 
of therapy has only a limited effect. Thus, the treatment 
led to a considerable reduction in the main androgens 
levels. The decrease in the LH concentration 5,19±1,12 
mIU/ml and the values of LH/FSH 0,97±0,21 (P < 0,05) 
correlated with the decrease in testosterone concentra-
tion and ovarian volume (8,79±1,34 cm3, P < 0,05) due 
to the suppression of LH-dependent synthesis of andro-
gens. Besides, we revealed a strong direct correlation 
between the LH level on the one hand, and ovarian vol-
ume and the An level on the other hand (14–16).
In patients with CHA+LPD, the prevalent component 
is abnormal steroidogenesis in adrenal glands. The in-
creased functional capacity of the adrenal component 
gives rise to a resemblance of an unpronounced HA, 
which is seen as a slight increase in the main androgens 
levels. The hyperandrogenic state has a suppressive ef-
fect upon the growth and development of follicles in the 
ovaries, which causes a shrinkage of the preovulatory 
follicle down to 16,84±0,74 mm, (P < 0,05) on days 
11–15 of the menstrual cycle, a shift of ovulation (days 
16–18), low functional capacity of the yellow body – 
17,53±0,57 mm (P < 0,05), a change in hormonal pa-
rameters (a decrease of the E2 level on days 5–7 – 
157,77±16,12 pmol/l (P < 0,05), and a change in the P 
level on days 21–23 to 31,79±2,27 nmol/l, (P < 0,01). 
Apart from this, patients with CHA+LPD have typical 
insignifi cant dysfunctions of the reproductive system – 
menstrual dysfunctions in the form of dysmenorrhoea 
– 29,7%, premenstrual syndrome (PMS) – 53%, and 
metrorrhagia – 43% of all patients; they are clinical cri-
teria of luteal phase defi ciency.
In patients with LPD, we revealed a high incidence of 
reproductive losses – 32,4%, which was caused by mis-
carriage found in every fourth patient and progressed 
like a non-developing pregnancy till weeks 8–9 of ges-
tation. It is common knowledge that this state is associ-
ated with low functional capacity of the yellow body; 
chorionic gonadotrophin, whose important role consists 
in preventing regression and stimulating the work of the 
yellow body, starts to exert its effect only from days 
12–14 after insemination. This statement proves a need 
for progestogenic therapy to ensure recovery of the yel-
low body functional capacity and, as a consequence, to 
maintain a wanted pregnancy (17, 18). The positive ef-
fect of this treatment pattern relies on normalization of 
folliculogenesis in the ovaries, which manifests itself in 
the growth of the preovulatory follicle (20,97±1,32 mm, 
P < 0,05) and the appearance of a functionally active 
yellow body (21,36±0,78 mm, P < 0,05). This treatment 
pattern led to onset of pregnancy in 68,3% of the cases 
considered.
142
Gynaecol Perinatol 2016;25(4):139–145 Abdulatipovna Saidova R. Recoverability of reproductive system…
Discussion
The therapy of CHA+LPD patients continued only 
until normalization of the level of androgens. The treat-
ment combining hormonal contraceptives and progesto-
gens made it possible to normalize the reproductive sys-
tem function, increase the estradiol activity during the 
menstrual cycle and make the yellow body active.
The treatment of LPD and stimulation of ovulation in 
the CHA+A patients were conducted in accordance with 
the conventional scheme. Stage 1 involved prescription 
of COCs for 4-6-8 months. The exact duration of the 
course depended on normalization of the main indicators 
of PCOS: LH <8, ovarian volume <8 cm3. In case of inef-
fi ciency after 4–6 months, the next stage (Stage 2) in-
cluded stimulation of ovulation with Clostilbegyt (Clo-
miphene) in the daily dosage of 50 mg from day 5 till day 
9 of the cycle; the course was repeated 2–3 times. Stage 
3 included the use of gonadotropins (recombinant FSH) 
in the daily dose of 100 IU, combined with stimulation of 
physiological ovulation. When the reproductive system 
state was normalized, we determined the steroid profi le 
parameters and evaluated the levels of estradiol and the 
main androgens (TT, FT, An, and DHT).
CHA – combined hyperandrogenism; An – androstenedione; DHT – dihydrotestosterone; E2 – estradiol; 
FT – free testosterone; TT – total testosterone.
Figure 1. Steroid hormone indicators and their ratios in the group of patients with CHA and anovulation, 
before and after treatment, days 21–23 of the cycle.
CHA+LPD – combined hyperandrogenism + luteal phase defi ciency; An – androstenedione; 
DHT – dihydrotestosterone; E2 – estradiol; FT – free testosterone; TT – total testosterone.
Figure 2. Steroid hormone indicators and their ratios in the group of patients with CHA and LPD 
before and after treatment, days 21–23 of the cycle.
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In case of the recovery of ovulatory cycles, the pa-
tients with anovulation and CHA are recommended to 
continue a therapy similar to that for patients with LPD 
– in order to normalize the functional capacity of the 
yellow body and the parameters of androgenic pathobo-
lism, because, in accordance with the results of our 
study, some of the patients with CHA+A were moving 
to the CHA+LFD group (78,6%). Besides, the therapy 
in the CHA+A group helped to reduce the incidence of 
menstrual disorders; the most severe form of the dys-
function, amenorrhea, was not detected in any of the 
patients after the treatment (being 9,1% prior to it). Op-
somenorrhea manifestations decreased to 12,4%. In 
case of preparing for pregnancy and infertility treat-
ment, the therapy should continue to be given until 
pregnancy. The post-treatment fertility indicator (onset 
of pregnancy) for the patients from this group of CHA 
reached 66,7%; the mean duration of therapy was 
7,62±0,64 months.
E2 belongs to the most biologically active com-
pounds, its indicator is the key criterion determining the 
functional capacity of a female reproductive system 
(19). This fact can be confi rmed by the results of our 
study, whereby in patients with CHA+LPD we revealed 
a hypo-estrogenic state (157,77±16,12 pmol/l) on days 
5–7 that exacerbated the hyperandrogenic state. A low 
E2 level in patients with CHA+LPD determines high 
fi gures of the ratio between androgens and estrogens, 
which is clinically manifested as pronounced skin 
symptoms of a real HA (acne – 43%, hirsutism – 
11,43±0,65 points). The results of these relations evalu-
ation on days 5–7 of the menstrual cycle in the CHA+
LPD group demonstrated higher values for the ratio 
DHT/E2 (10,51±1,02, P < 0,01) in comparison with the 
group of patients with CHA+A (DHT/E2=9,49±0,77). 
This parameter appreciably decreased in the second 
group (to 3,12±0,28, P < 0,01) and remained unaltered 
for the fi rst group (8,87±1,78, P < 0,01) in the course of 
the menstrual cycle. It should be noted that in the course 
of the menstrual cycle, these values reduced almost two 
times due to a signifi cant increase in Е2 – 559,28±37,84 
pmol/l (P < 0,01) (Figure 1).
According to the results of our study, in the course 
of a pathogenetic therapy, patients with CHA+LPD 
demonstrated a statistically signifi cant decrease in the 
androgens levels and a noticeable rise in the E2 level 
(Figure 2).
Patients with a luteal phase defi ciency require indi-
vidual correction of their hyperandrogenic state by a 
therapy in combination with progestogens and natural 
progesterone analogues via a pattern standard for LPD 
cases (20). What confi rms this statement in the fi rst 
place is the fact that patients with an HA and infertility 
demonstrated both delayed ovulation periods (the mean 
duration of the menstrual cycle is 40,15±3,79 days) and 
the syndrome of anovulating follicle, which can be de-
tected only through ultrasound monitoring of folliculo-
genesis. The positive effect of this treatment patterm is 
refl ected in the following processes: normalization of 
folliculogenesis in the ovaries, namely, the growth of 
the preovulatory follicle, the appearance of a function-
ally active yellow body, an increase in the E2 level on 
days 5–7 of the menstrual cycle and in the P level on 
days 21–23 (83,8%), and also the onset of pregnancy 
(68,4%). In the group of CHA+LPD patients undergo-
ing pathogenetic therapy, we observed a statistically 
signifi cant reduction in the following parameters: TT, 
FT, An, and DHT, as well as a noticeable increase in the 
E2 level both on days 5–7 and days 21–23 of the men-
strual cycle, which was practically the same as in the 
control group. In addition to the considerable increase 
in the E2 level and reduction in the androgens level, we 
revealed a statistically signifi cant decrease of their ratio 
values, which had a clinical manifestation in a better 
skin health (Figure 2).
The results of our study show that pregnancy started 
only in the cases of normalization of all androgen me-
tabolism indicators (TT, FT, DHT, and An) and their 
ratios to estrogens (TT/E2, DHT/E2) in the fertility cy-
cle. In early gestation (weeks 5–8), maintenance of 
pregnancy is possible only if the androgens levels are 
decreasing, while the concentrations of E2 and human 
chorionic gonadotrophin are rising. The results of this 
study give grounds to claim that the most important pa-
rameters in terms of diagnostics and treatment control 
are the indicators of the main androgens (TT, FT, An 
and DHT), the indicators of estradiol and progesterone 
measured dynamically during the menstrual cycle, as 
well as their ratio. Thus, it should be noted that hor-
mone correction of diagnosed reproductive dysfunc-
tions in both groups with CHA, with regard to androgen 
metabolism indicators and change in the haemostasis 
system, allows achieving normalization of hormonal 
values, menstrual function, and a sustained recovery of 
the reproductive system functional capacity.
Conclusion
For patients with CHA+А, it is typical to demonstrate 
pronounced menstrual (opsomenorrhea with menstrual 
delays up to 2 months, and/or amenorrhea) and repro-
ductive (hormonal infertility) dysfunctions; enlarge-
ment of ovaries > 9 cm3; an increase in the value of LH/
FSH > 2 and in the main androgens levels (TT, FT, An). 
Androgen levels in patients with anovulation were 
greatly different from those in the control group both on 
days 5–7 and 21–23 of the menstrual cycle. Their level 
of E2 was not statistically changing in the course of the 
menstrual cycle, which, taking into account the low 
level of progesterone, confi rms the presence of an an-
ovulatory state.
Increased androgens levels in patients with CHA+A 
result from anovulation; besides, a progressive increase 
in the levels of sex steroids during the menstrual cycle 
exacerbates the anovulatory state, which manifests it-
self as the increased LH level and LH/FSH ratio, en-
largement of ovaries with follicles sized 8–10 mm in 
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diameter, and absence of any dynamic changes of the 
E2 level and the value of P.
Patients with CHA+LPD tend to show such charac-
teristics as minor menstrual dysfunctions (delayed ovu-
lation). In their cases, miscarriage is caused by lower 
functional activity of the yellow body, by changes of 
hormonal parameters as well as by a pronounced hyper-
androgenic state. The androgenic indicators in patients 
with LPD (tested on days 5–7 of the menstrual cycle) 
were practically similar to those of patients having an-
ovulation (TT, FT, An, DHT) (21). However, in the 
course of the menstrual cycle, these indicators were 
close to the values of the control group, while the E2 
and P levels became twice higher, which is the evidence 
of an ovulatory cycle (Figure 1).
The hyperandrogenic state of patients with CHA+LPD 
has a suppressive effect upon the growth and develop-
ment of follicles in the ovaries, which causes shrinkage 
of preovulatory follicles, a shift of ovulation, a low 
functional capacity of the yellow body, and a change in 
hormonal parameters (reduction of the E2 level on days 
5–7 of the menstrual cycle and a decrease in the P level 
on days 21–23).
The effi cacy of the treatment aimed at ensuring a 
functional recovery of the reproductive system in wom-
en with HA depends on the precise differential diagno-
sis of the HA character and on the state of the reproduc-
tive system.
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OPORAVAK REPRODUKTIVNE FUNKCIJE 
U PACIJENATA SA ZDRUŽENIM HIPERANDROGENIZMOM
Ravzat Abdulatipovna Saidova
Izvorni znanstveni članak
Ključne riječi:  hiperandrogenizam, anovulacija, nedostatak lutealne faze, sindrom policističnih jajnika, testosteron, 
dihidrotestosteron, neplodnost
SAŽETAK. Uvod. Hiperandrogenizam uzrokovan poremećajem rada nadbubrežne žlijezde (HA) ima negativan učinak na 
ženski reproduktivni sustav (RS), dok je ovarijski HA preduvjetovan anovulacijskim stanjem. Postoje kontradiktorna 
mišljenja o utjecaju različitih androgena na funkcije ženskog reproduktivnog sustava. Glavni kriteriji procjene i važnosti 
tih čimbenika ostaju nedefi nirani. Cilj. U istraživanju je ispitano ukupno 105 žena, uključujući kontrolnu skupinu žena 
u dobi od 19 do 37 godina (srednja dob 27,39 ± 0,75), te pacijentice s menstruacijom (opso i oligomenorrhea) i repro-
duktivnim (neplodnost i pobačaji). Metode. Tijekom menstrualnog ciklusa provedena su hormonska ispitivanja, 5–7. i 
21–23. dana, uz procjenju razine lučenja peptida i steroidnih spolnih hormona. Rezultati. Kombinirana HA je jedan od 
vodećih patogenih uzroka menstrualnih i reproduktivnih poremećaja. Anovulacijska stanja uzrokuju porast razine 
glavnih androgena, a manjak lutealne faze posljedica je negativnog utjecaja HA. Pojedinačna terapija temeljena na 
 patogenezi omogućava oporavak ovulacije i osiguranje trudnoće na pozadini normalizacije metabolizma androgena i 
drugih pokazatelja funkcioniranja reproduktivnog sustava. Zaključak. Kriteriji za diferencijalnu dijagnostiku hiper-
androgenih stanja i procjenu reproduktivnih disfunkcija omogućuju pronalaženje individualnog uzorka liječenja.
